

ADVANCE VOTING FORM

Herantis Pharma Plc Extraordinary General Meeting on 2 December 2020

With this form, I/we authorize Euroclear Finland Oy (“**Euroclear**”), the advance voting service provider for Herantis Pharma Plc Extraordinary General Meeting 2020, to register my/our votes with the shares I/we own/represent in certain items of agenda of Herantis Pharma Plc Extraordinary General Meeting 2020

I/we understand that voting in advance by submitting this form requires that the shareholder has at least one valid Finnish book-entry account. The number of advance votes is confirmed on the Finnish record date of the Extraordinary General Meeting (eight business days before the Meeting) based on the holding in the book-entry account.

I/we give my/our consent that, if needed, Euroclear may check from the Finnish book-entry system shareholder's book-entry account number in order to register the advance votes.

Shareholder's name	
Finnish personal ID-code, business ID (Y-tunnus), or Euroclear artificial ID (X-tunnus)	
Phone number	
Finnish book-entry account number (if known*)	

*Please note that you may vote in advance also electronically in the address <https://herantis.com/event/extraordinary-general-meeting-2020/> if you know the number of your Finnish book-entry account.

Voting instructions:

I/we authorize Euroclear Finland Oy to register my/our votes with the shares I/we own/represent in each of the items of the agenda of the Meeting as indicated with a cross (X) below.

If no voting instructions have been indicated below, or if there are more than one voting instructions on the same item, or if other text or markings other than a cross (X) have been used to indicate a voting instruction, the item will be marked as “No action” when Euroclear registers the votes. This means that shareholder's shares are not taken into consideration in the item in question. Shareholder's shares are not considered as shares represented at the meeting and the votes are not counted as cast votes with regard to the item in question.

I/we understand that if I/we give advance votes as a representative of an entity (incl. estate), the legal representative of the entity or a person authorized by the entity must provide necessary documents to prove the right to represent the entity (e.g. trade register extract or board resolution). Documents are requested to be attached to this advance voting form. If the documents are not submitted during the advance voting period or they are otherwise incomplete, the shares of the entity will not be included as shares represented at the Extraordinary General Meeting.

It is recommended that a Finish book-entry account holder votes in advance electronically in the address <https://herantis.com/event/extraordinary-general-meeting-2020/>. In a situation where the Finnish book-entry account holder has voted in advance both electronically and via this advance voting form, Euroclear will register the most recent voting instruction in the book-entry account.

[Continues on the next page]

Matters to be resolved at the Herantis Pharma Plc Extraordinary General Meeting 2020

Agenda items 6 to 8 cover proposals of the Board of Directors of Herantis Pharma Plc to the Extraordinary General Meeting in accordance with the notice of the Meeting. "Abstain from voting" means giving an empty vote and shares are considered to be represented in the meeting, which is meaningful in resolutions requiring qualified majority (e.g. agenda items 6, 7 and 8). In qualified majority items all shares represented at the meeting are taken into account and abstentions thus have the same effect as votes Against/No. Therefore, abstaining from voting affects the voting result. Shareholders should be aware of this, especially if giving a vote against is not their intention.

Matter to be resolved	For/Yes	Against/No	Abstain from voting
6. Authorization of the board of directors to decide on issuing shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Amendment to terms of "2016 I" option rights	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Authorization of the board of directors to decide on issuing option rights and other special rights entitling to shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Place and date	
Signature	
Name in block letters	

To be returned in a completed and signed form either by email to yhtiokokous@euroclear.eu or by letter to Euroclear Finland Oy, Yhtiökokous / Herantis Pharma Plc, P.O. Box 1110, FI-00101 Helsinki. **The delivery must be received latest by 25 November 2020 by 10.00 a.m. (EET).**